Results 101 to 110 of about 4,688,320 (340)

Tongue features of patients with coronavirus disease 2019: a retrospective cross-sectional study

open access: yesIntegrative Medicine Research, 2020
Background: Traditional Chinese medicine (TCM) has been widely used in the treatment of coronavirus disease 2019 (COVID-19). Tongue features should be referred for diagnosis and treatment of diseases in TCM.
Wentai Pang   +8 more
doaj  

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

open access: yesMolecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti   +10 more
wiley   +1 more source

A Randomized, Sham-Controlled Trial on the Efficacy and Safety of Electroacupuncture for Lumbar Disc Herniation with Radiculopathy: Rationale and Study Protocol

open access: yesJournal of Pain Research
Yuwei Yang,1,* Liting Liu,1,* Lixia Yuan,1 Xiaoya Liu,1 Haoying Ding,2 Xu Zhou,3 Qianan Cao4 1Graduate School, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, 330004, People’s Republic of China; 2The First Department of ...
Yang Y   +6 more
doaj  

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

open access: yesMolecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit   +19 more
wiley   +1 more source

Using PICO to Align Medical Evidence with MDs Decision Making Models [PDF]

open access: yes, 2013
Modern medicine is characterized by an “explosion” in clinical research information making practical application of Evidence-Based Medicine (EBM), problematic for many clinicians.
Farion, K.   +3 more
core   +1 more source

Reconstructing data : evidence-Based Medicine and Evidence-Based Public Health in context [PDF]

open access: yes, 2006
The emergence of Evidence-Based Medicine (EBM) as the gold-standard practice in biomedicine and public health practices represents a significant epistemological turn in modern medicine.
Davidovitch, Nadav
core   +6 more sources

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

open access: yesMolecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson   +11 more
wiley   +1 more source

Bad news: analysis of the quality of information on influenza prevention returned by Google in English and Italian [PDF]

open access: yes, 2015
Information available to the public influences the approach of the population toward vaccination against influenza compared with other preventative approaches.
Allam   +38 more
core   +3 more sources

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy